Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | TLR2 | O60603 | 2/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30777648 | 1.00 | MDM4 (0.54) | MDM4TP53TLR2MDM2CASP3 | |
| SCHEMBL9062116 | 0.91 | MDM4 (0.58) | MDM4TP53TLR2MDM2CASP3 | |
| SCHEMBL9062110 | 0.91 | MDM4 (0.58) | MDM4TP53TLR2MDM2CASP3 | |
| SCHEMBL22154133 | 0.88 | MDM4 (0.56) | MDM4TP53TLR2MDM2CASP3 | |
| SCHEMBL29768618 | 0.87 | FDFT1 (0.57) | MDM4TP53TLR2MDM2CASP3 | |
| SCHEMBL800305 | 0.87 | FDFT1 (0.57) | MDM4TP53TLR2MDM2CASP3 | |
| SCHEMBL4600701 | 0.87 | FDFT1 (0.57) | MDM4TP53TLR2MDM2CASP3 | |
| SCHEMBL29762010 | 0.87 | FDFT1 (0.57) | MDM4TP53TLR2MDM2CASP3 | |
| SCHEMBL29400804 | 0.87 | FDFT1 (0.57) | MDM4TP53TLR2MDM2CASP3 | |
| SCHEMBL800035 | 0.87 | FDFT1 (0.57) | MDM4TP53TLR2MDM2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517855-B2 | Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof | ATTENUON, LLC (US) | 2009-04-14 | — | — | US | disclosed |
| EP-1594521-A4 | PEPTIDES WHICH INHIBIT ANGIOGENESIS, CELL MIGRATION, CELL INVASION AND CELL PROLIFERATION, COMPOSITIONS AND USES THEREOF | ATTENUON LLC (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1594521-A2 | PEPTIDES WHICH INHIBIT ANGIOGENESIS, CELL MIGRATION, CELL INVASION AND CELL PROLIFERATION, COMPOSITIONS AND USES THEREOF | Attenuon, LLC (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20040162239-A1 | Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof | ATTENUON LLC | 2004-08-19 | — | — | US | disclosed |
| WO-2004047771-A2 | PEPTIDES WHICH INHIBIT ANGIOGENESIS, CELL MIGRATION, CELL INVASION AND CELL PROLIFERATION, COMPOSITIONS AND USES THEREOF | ATTENUON, LLC. (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162239-A1 | Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof | HDGF, VIP, PGF | MDM4 2810/4885TP53 1183/4885TLR2 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.